Molecular analysis of Bcl-2/IgH chimeric gene before, during, and after CHOP chemotherapy
| . | PCR-negative . | |
|---|---|---|
| Bone marrow (%) . | Peripheral blood (%) . | |
| At diagnosis | 0/128 | 0/128 |
| After 3 cycles of CHOP | 32/111 (29)* | 35/113 (30) |
| After 6 cycles of CHOP | 43/118 (36)† | 43/121 (35) |
| . | PCR-negative . | |
|---|---|---|
| Bone marrow (%) . | Peripheral blood (%) . | |
| At diagnosis | 0/128 | 0/128 |
| After 3 cycles of CHOP | 32/111 (29)* | 35/113 (30) |
| After 6 cycles of CHOP | 43/118 (36)† | 43/121 (35) |
In 13 patients the molecular evaluation on bone marrow aspirates was not performed because of patients' and physicians' refusal. In 4 patients the harvested marrow was not adequate for molecular analysis.
Seven patients were not evaluated because they were clinically not responsive to CHOP. In one patient the harvested marrow was not adequate for molecular analysis. In 2 patients the evaluation was not performed because of the patients' and physicians' refusal.